Milestone Pharmaceuticals Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of June 30, 2026, Milestone had cash, cash equivalents, and short-term investments totaling $170.6 million, up from $106 million at the end of 2025.

Product Revenue: For Q2 2026, product revenue was $0.6 million, with a total of $0.8 million for the first half of the year. This is a notable increase from zero revenue in the same periods of 2025.

Expenses:

R&D expenses for Q2 were $3.5 million, down from $3.7 million in Q2 2025.

Selling, general, and administrative expenses surged to $22.6 million in Q2 2026, compared to $8.9 million in Q2 2025, attributed to launch-related costs.

Net Loss: The net loss for Q2 2026 was $28.6 million ($0.21 per share), compared to a loss of $13 million ($0.20 per share) in Q2 2025. For the first half of 2026, the net loss totaled $54.7 million ($0.41 per share), compared to $33.7 million ($0.51 per share) in the prior year.

2Strategic Updates and Business Highlights

Product Launch: CARDAMYST, a self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), has seen significant uptake with over 1,200 prescriptions written in Q2, up from approximately 300 in Q1. Total unique prescribers increased to over 800.

Market Access: Coverage for CARDAMYST has improved to over 50% of commercially insured lives, up from 25% at the end of Q2. This was driven by formulary decisions from major insurers like UnitedHealthcare.

Clinical Development: The company has initiated a Phase III trial for etripamil targeting atrial fibrillation with rapid ventricular rate (AFib-RVR), leveraging insights from the successful PSVT program.

3Forward Guidance and Outlook

Milestone expects continued growth in prescriptions and revenues as commercial coverage expands and patient activation initiatives are launched. The company is optimistic about achieving greater penetration in the market, particularly as awareness and access improve.

The marketing application with the European Medicines Agency is on track for a decision in the first half of 2027, with potential for global expansion if successful.

4Bad News, Challenges, or Points of Concern

High Expenses: The significant increase in SG&A expenses raises concerns about the sustainability of losses as the company invests heavily in the launch of CARDAMYST.

Dependency on Coverage: The initial low coverage (25% of commercially insured lives) limited revenue generation, and while improvements have been made, the transition to higher revenues will depend on continued success in securing additional coverage.

Market Risks: The company faces risks associated with the competitive landscape and the need for ongoing education among prescribers about CARDAMYST, particularly as it is a new treatment in a long-unchanged market.

5Notable Q&A Insights

Prescribing Trends: There is a mix of early adopters and one-time prescribers, with a strong engagement from electrophysiologists. The sales strategy will focus on both expanding the base of prescribers and encouraging repeat prescriptions.

Patient Activation: The company plans to enhance patient awareness through targeted digital marketing efforts, which are expected to begin impacting prescription growth as coverage stabilizes.

Pricing and Rebates: The average selling price is currently affected by high denial conversion rates due to low coverage, but this is expected to improve as coverage increases.

AFib-RVR Trial Risks: The Phase III trial for AFib-RVR carries risks related to patient-reported outcomes and potential misdiagnosis of events, which could affect trial execution. Overall, Milestone Pharmaceuticals is positioned for growth in the second half of 2026, driven by improved market access and ongoing patient engagement strategies, although challenges remain regarding financial sustainability and market penetration.